Stryker (NYSE:SYK - Get Free Report) is set to announce its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of $2.78 per share for the quarter. Stryker has set its FY24 guidance at $11.90-12.10 EPS and its FY 2024 guidance at 11.900-12.100 EPS.Individual interested in registering for the company's earnings conference call can do so using this link.
Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The company had revenue of $5.42 billion for the quarter, compared to analysts' expectations of $5.40 billion. During the same period in the previous year, the business posted $2.54 EPS. The business's revenue for the quarter was up 8.5% compared to the same quarter last year. On average, analysts expect Stryker to post $12 EPS for the current fiscal year and $13 EPS for the next fiscal year.
NYSE SYK opened at $367.23 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. The company has a market capitalization of $139.90 billion, a PE ratio of 41.92, a price-to-earnings-growth ratio of 2.85 and a beta of 0.91. Stryker has a 52-week low of $255.22 and a 52-week high of $374.63. The company has a 50-day simple moving average of $356.63 and a 200 day simple moving average of $343.34.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.80 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.87%. Stryker's payout ratio is 36.53%.
Several research analysts have recently weighed in on SYK shares. Wolfe Research started coverage on Stryker in a research note on Tuesday, September 10th. They set an "outperform" rating and a $405.00 price target for the company. BTIG Research boosted their price target on shares of Stryker from $374.00 to $383.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Stifel Nicolaus dropped their price target on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. Barclays raised their price target on Stryker from $374.00 to $402.00 and gave the stock an "overweight" rating in a report on Thursday, August 1st. Finally, StockNews.com raised Stryker from a "hold" rating to a "buy" rating in a report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $381.16.
Read Our Latest Analysis on Stryker
In other news, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company's stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Viju Menon sold 600 shares of the company's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company's stock, valued at $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the firm's stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares of the company's stock, valued at $949,716. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 220,068 shares of company stock worth $71,811,372 over the last quarter. Corporate insiders own 5.90% of the company's stock.
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.